Trial
NCT03684642
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi
Collaborators
Hanmi Pharmaceutical Company Limited
Condition
Type 2 Diabetes Mellitus
Intervention
Efpeglenatide
Why stopped
Sponsor decision to cancel TRIAL, not related to safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-01